ZIOPHARM Oncology Inc (ZIOP) : Average target price received by ZIOPHARM Oncology Inc (ZIOP) is $14 with an expected standard deviation of $9.9. The most aggressive target on the stock is $21, whereas the most downbeat target is $7. 2 financial analysts are currently covering the stock.
ZIOPHARM Oncology Inc (ZIOP) : Zacks Investment Research ranks ZIOPHARM Oncology Inc (ZIOP) as 2, which is a Buy recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 3 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 2.5, which indicates as a Buy.
Also, Wells Fargo upgrades its rating on ZIOPHARM Oncology Inc (NASDAQ:ZIOP). Analysts at the Wells Fargo have a current rating of Market Perform on the shares. The shares were previously rated Underperform. The rating by the firm was issued on August 10, 2016.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP): The stock opened at $5.18 on Thursday but the bulls could not build on the opening and the stock topped out at $5.24 for the day. The stock traded down to $4.90 during the day, due to lack of any buying support eventually closed down at $4.99 with a loss of -1.58% for the day. The stock had closed at $5.07 on the previous day. The total traded volume was 1,537,585 shares.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).